OWC Pharmaceutical Research Corp (OWCP)

[DD_dempsey]

OWCP-mega MATERIAL 8K EVENT- Getting 300k loan-non interest! details herein!

I was so clear that OWCP needed 300k according to their most recent filings. This loan is the BEST possible loan we could have received as its non-interest bearing, non convertible to shares AND due in 36 months.

I will spend some more time later explaining in detail the new effect this has on the cost per share and expected valuation based on this new material evidence.

Do NOT misunderstand what this 8k is folks! This is our assurance....that they won't need to SELL 300k worth of stock onto us to pay off SHEBA this year.

Entry under .01 pps will be green. This will fluctuate folks! Understands what you own. The company was also clear they are releasing about but no more than 4mil shares to a company insider. This may have wild swings today as intelligent investors savvy with my prior posts and reading 10k's will understand that this is now a potential hedge fund play --- .05 is not out of the question by end of year. Realistically- this will provide a few good entries today and I firmly expect stronger hands to prevail and leave us at .01 break. Between this one, BABL and FTPM- were going to have a massive green Friday. Congrats dude !

Read it here (or below): http://ih.advfn.com/p.php?pid=nmona&article=72563174&symbol=OWCP

Item 1.01. Entry Into A Material Definitive Agreement

On September 28, 2016, OWC Pharmaceutical Research Corp.’s wholly-owned Israeli subsidiary, One World Cannabis Ltd. (“OWC Ltd”), entered into a loan agreement (the “Loan Agreement”) with Medmar LLC , organized under the laws of the State of Maryland (“Medmar”), effective as of September 22, 2016 (the “Effective Date”), pursuant to which Medmar has agreed to loan OCW Ltd a total of $300,000 (the “Loan”) on a non-interest bearing basis, with no conversion rights. Medmar will fund the Loan in six equal installments of $50,000 each, as follows: (i) 1st installment was released to OWC Ltd on September 22, 2016; (ii) 2nd installment on October 1, 2016; (iii) 3rd installment on November 1, 2016; (iv) 4th installment on December 1, 2016; (v) 5th installment on January 1, 2017; and (vi) 6th installment on February 1, 2017. The Loan, as noted above, bears no interest, is not convertible, is due in 36 months from the Effective Date, and repayment shall be made only by the set off of royalties payable by Medmar to OWC Ltd, as discussed below.

The Loan Agreement further provides that: (i) prior to the full repayment of the Loan, which OWC Ltd may prepay at any time, if and to the extent Medmar is required to pay any royalties to OWC under a License Agreement dated March 17, 2016, Medmar shall set off such royalties from the outstanding principal balance of the Loan; (ii) OWC shall not be required to pay the Loan other than through the set off from the royalties; and (iii) the Loan is a non-recourse loan, meaning that if and to the extent that the royalties are insufficient for any reason in order to fully repay the Loan, Medmar waived any right and/or claim to any deficiency.

In addition, the Loan Agreement also provides that: (i) subject to Medmar funding the entire Loan, Medmar shall receive the exclusive right to manufacture, produce, publicize, promote and market the OWC’s Licensed Products (as defined in the above-referenced License Agreement) in any state in the U.S., subject to a new license agreement to be negotiated and signed between the parties with respect to each and every state; (ii) the rights to be granted to Medmar under (i) above shall expire within three (3) years subject to certain conditions and limitations; and (iii) the right of first refusal agreement between the parties that was executed on February 8, 2016 providing Medmar certain rights in connection with the commercialization of Licensed Products in the States of Hawaii and Pennsylvania be terminated.

The foregoing description of the Loan Agreement are qualified in their entirety by reference to the full text of thereof, a copy of which is attached hereto as Exhibit 10.9, which is incorporated herein in its entirety by reference.

Item 9.01 Financial Statements and Exhibits.

(b) The following document is filed an exhibit to this current report on Form 8-K or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.

Exhibit No. Description